From a literature search, expert survey, and direct engagement of MS patients and caregivers from seven European countries, 10 clinical questions were formulated about the following topics:
- Symptomatic treatments;
- Multidisciplinary rehabilitation;
- Advanced care planning;
- General palliative care;
- Specialist palliative care;
- Caregiver training and education;
- Caregiver practical and emotional support;
- MS healthcare professionals’ training/education in palliative care;
- Palliative care healthcare professionals’ training/education in MS care; and
- Discussion with healthcare professionals about the wish of hastening death.
Dr Alessandra Solari (Carlo Besta Neurological Institute, Italy) and co-authors found no studies related to only 4 of these 10 questions. Meta-analysis was possible for 1 question (symptom management) and individual participant data meta-analysis for 2 questions (general and specialist palliative care). Of ten publications on palliative care, three were randomised controlled studies and one qualitative study. Of these, two compared home-based specialist palliative care to usual care, and one compared home-based general palliative care to usual care [2].
Recommendations about palliative care and hastened death discussion were:
- People with severe MS should be offered home-based palliative care, either by healthcare professionals with good basic palliative care skills and knowledge (general palliative care) or a multi-professional team of palliative care specialists (specialist palliative care).
- People with severe MS should be offered in- or outpatient palliative care. Patient preference, conditions, and availability of palliative care services should be taken into account.
- MS patients should be encouraged to discuss their wishes about future care, including the restriction of treatment or interventions and the wish of hastened death.
- Healthcare professionals should be aware of the risk factors for the wish of hastened death, including depression, isolation, restricted abilities, and encourage the discussion of these issues and the appropriate management.
- Köpke S, et al. Eur J Neurol. 2019;26:41-50.
- Solari A, et al. ECTRIMS 2019, abstract 337.
Posted on
Previous Article
« Letter from the Editor Next Article
Late-breaking: Continuation of natalizumab or interruption during pregnancy »
« Letter from the Editor Next Article
Late-breaking: Continuation of natalizumab or interruption during pregnancy »
Table of Contents: ECTRIMS 2019
Featured articles
Towards a Comprehensive Assessment of MS Course
Cognitive assessment in MS
Late-breaking: Role for CSF markers in autoimmune astrocytopathies
Targeted therapies for NMOSD in development
Monitoring and Treatment of Progressive MS
Challenges in diagnosing and treating progressive MS
Risk factors for conversion to secondary progressive MS
Transplantation of autologous mesenchymal stem cells
Sustained reduction in disability progression with ocrelizumab
Late-breaking: Myelin-peptide coupled red blood cells
Optimising Long-Term Benefit of MS Treatment
Induction therapy over treatment escalation
Treatment escalation over induction therapy
Influence of age on disease progression
Exposure to DMTs reduces disability progression
Predicting long-term sustained disability progression
Treatment response scoring systems to assess long term prognosis
Safety Assessment in the Post-Approval Phase
Use of clinical registries in phase 4 of DMT
Genes, environment, and safety monitoring in using registries
Risk of hypogammaglobulinemia and rituximab
Determinants of outcomes for natalizumab-associated PML
Serum immunoglobulin levels and risk of serious infections
EAN guideline on palliative care
Pregnancy in the Treatment Era
The maternal perspective: when to stop/resume treatment and risks for progression
Foetal/child perspective: risks related to drug exposure and breastfeeding
Patient awareness about family planning represents a major knowledge gap
Late-breaking: Continuation of natalizumab or interruption during pregnancy
Related Articles
November 25, 2020
Safety and efficacy of cladribine, glatiramer acetate, and more
July 30, 2019
No increased MS relapse risk postpartum
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com